Page 903 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

44 MOLÉCULES EN DEVELOPPEMENT 861

ANGIOGENÈSE
KESTELL P. et al., Plasma disposition, metabolism and excretion of the experimental
antitumor agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit,
Cancer Chemother. Pharmacol., 1999, 43, 323-330.
HWANG J.-T. et al., Reaction of the hypoxia-selective antitumor agent tirapazamine with
a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabo-
lites can serve as surrogates for molecular oxygen in radical-mediated DNA damage
reactions, Biochem., 1999, 38, 14248-14255.
PEUCKMANN V. et al., Potential novel uses of thalidomide. Focus on palliative care,
Drugs, 2000, 60 (2), 273-292.
WEDGE S.R. et al., ZD4190: an orally active inhibitor of vascular endothelial growth fac-
torsignaling with broad-spectrum antitumor efficacy, CancerRes., 2000, 60, 970-975.
LAIRD A.D. et al., SU 6668 is a potent antiangiogenic and antitumor agent that induces
regression of established tumors, Cancer Res., 2000, 60, 4152-4160.
SUN l., McMAHON G., Inhibition of tumor angiogenesis by synthetic receptor tyrosine
kinase inhibitors, Drug Discovery To-day, 2000, 5 (8), 344-353.
MOSS M.L. et al., TAGE and other ADAM proteases as targets for drug discovery, Drug
Discovery To-day, 2001, 6 (8), 417-424.
FODA H.D., ZUCKER S., Matrix metalloproteinases in cancer invasion, metastasis and
angiogenesis, Drug Discovery To-day, 2001, 6 (9), 478-482.
MATTER A., Tumor angiogenesis as a therapeutic target, Orug Discovery To-day, 2001,
6 (19), 1005-1024.
PATTERSON L.H., McKEOWN S.A., AQ4N : a new approach to hypoxia-activated can-
cer chemotherapy, Br. J. Cancer, 2001, 83, 1589-1593.
FUCHS T. et al., 3-amino-1,2,4-benzotriazine 4-oxide : characterization of a new meta-
bolite arising from bioreductive processing of the antitumoragent 3-amino-1,2,4-ben-
zotriazine 1,4-dioxide (tirapazamine), J. Org. Chem., 2001, 66, 107-114.
LYDEN D. et al., lmpaired recruitment of bone-marrow-derived endothelial and hemato-
poietic precursor cells blocks tumor angiogenesis and growth, Nat. Med., 2001, 7,
1194-1201.
EGEBLAD M. et al., MMP-inhibitors in cancer, Nature Rev. Cancer, 2002, 2, 163-176.
CARMELIET P. et al., Angiogenesis in cancer and other diseases, Nature, 2002, 407,
249-257.
ANTAGONISMES MDR
NEWMAN M.J., Discovery and characterization of OC 144-093 a novel inhibitor of P-gly-
coproteine-mediated multidrug resistance, Cancer Res., 2000, 60, 2964-2972.
APPROCHES ANTISENS ET ANTIGÈNE
CROOKE S.T., Potential roles of antisens technology in cancer chemotherapy, Onco-
gene, 2000, 19, 6651-6659.
PAWLAK W. et al., Antisensetherapy in cancer, CancerTreatment Re., 2000, 26, 333-350.
HÉLÈNE C., Antisense and antigene strategies for cancer therapy. From basic concepts
to the clinic, in Eurocancer 2000, Libbey J. ed, Eurotext, 2000, 139-140.